Compare Danaher Corporation (DHR) vs Manhattan Associates Inc (MANH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Danaher Corporation vs Manhattan Associates Inc — how do they compare? Danaher Corporation trades at $219.87 (market cap $152.87B), while Manhattan Associates Inc trades at $204.89 (market cap $12.06B). The key difference: Danaher Corporation is far larger — about 12.7× Manhattan Associates Inc's market cap, and Danaher Corporation pays a 0.74% dividend while Manhattan Associates Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Danaher Corporation for 69 Days and Manhattan Associates Inc for 12 Days on average.
| DHR | MANH | |
|---|---|---|
Market Cap | $152.87B | $12.06B |
Volume | 5,228,698 | 376,150 |
Sector | Health | Technology |
52-Week High | $242.05 | $223.76 |
52-Week Low | $161.91 | $120.88 |
Typical Hold Time | 69 Days | 12 Days |
Enterprise Value | $175.08B | $11.93B |
Dividend Yield | 0.74% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Danaher (DHR) trades at $217.46, down 0.47% on the day, with a bullish technical signal from moving averages and support at $214. The company shows strong profitability with a 58.51% gross margin and has beaten EPS estimates for three consecutive quarters. Recent news includes a declared $0.40 dividend payable in October 2026 and significant institutional buying, such as Bank of America's new $993.8 million stake in Q2 2026.
The outlook is positive with a consensus price target of $230.31, implying 5.9% upside, supported by 70% analyst buy ratings. Risks include elevated valuation multiples like a P/E of 38.76 and fluctuating cash flows, but earnings growth in biotechnology and steady revenue provide a solid foundation for investor confidence.
MANH trades at $204.89, up 1.38% on the day, with a bullish technical trend and strong profitability metrics including a 96.38% ROE and 18.67% net income margin. The stock has consistently beaten earnings estimates in recent quarters, though high valuation ratios like a P/E of 59.26 suggest premium pricing. Recent news includes a mix of positive product launches and ongoing legal investigations into fiduciary duties.
The outlook is cautiously optimistic, supported by analyst consensus and solid fundamentals, but risks include the high valuation, potential legal overhangs, and a projected decline in net income for 2026. Upside potential exists toward the $210.50 consensus target if execution remains strong.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Danaher Corporation
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →About Manhattan Associates Inc
Manhattan Associates, Inc. is a global leader in supply chain and omnichannel commerce software. The company provides a comprehensive suite of cloud-based and on-premise solutions for warehouse management (WMS), transportation management (TMS), and order management (OMS). MANH's technology helps retailers, wholesalers, and manufacturers manage inventory, optimize logistics, and unify the shopping experience across physical and digital channels.
Read more on MANH →
